Hydralazine Adverse Effects and Clinical Management

Pharmacologic (Hemodynamic) Side Effects

Headache, flushing, and reflex tachycardia are the most frequently reported adverse effects in adults receiving hydralazine for hypertension or heart failure. These symptoms arise from the drug’s vasodilatory action. 1
Hypotension and palpitations commonly occur due to arterial vasodilation in patients treated with hydralazine. Clinicians should anticipate these hemodynamic changes, especially after dose initiation or escalation. 1
Nausea and other gastrointestinal complaints are frequently reported among hydralazine users. These symptoms are typically mild and dose‑related. 2

Hydralazine is frequently employed as an alternative antihypertensive in patients who cannot tolerate ACE inhibitors, because cough is a hallmark ACE‑inhibitor adverse effect and not associated with hydralazine. This substitution helps avoid ACE‑inhibitor‑induced cough while still providing blood‑pressure control. 2

If a patient on hydralazine develops a cough, clinicians should first assess for concurrent ACE‑inhibitor therapy, as ACE inhibitors are the likely cause of the cough. Hydralazine is often combined with other antihypertensives, making this assessment essential. 2
Progression of heart failure (e.g., pulmonary congestion) should be considered as an alternative explanation for cough in patients on hydralazine. This reflects the underlying disease rather than the medication. 3

Routine monitoring should include assessment for cardiovascular symptoms such as headache, palpitations, and tachycardia, which are the most common hydralazine‑related adverse effects. Early detection allows dose adjustment or adjunctive therapy. 1

Hydralazine is a direct arterial vasodilator that causes reflex tachycardia as a common side effect due to its vasodilatory mechanism of action, as noted by the American College of Cardiology 4, 5
The American College of Cardiology/American Heart Association guidelines specifically note that hydralazine is "associated with sodium and water retention and reflex tachycardia" 4

When using hydralazine for hypertension, it is typically administered 2-3 times daily (100-200 mg/day total), according to Circulation guidelines 5
Hydralazine is classified as a "direct vasodilator" in hypertension guidelines and is specifically noted to cause sodium and water retention and reflex tachycardia, which is why it is typically recommended to be used with a diuretic and beta-blocker to counteract these compensatory mechanisms, as recommended by the American College of Cardiology 4, 5